- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Immuneering Corp(IMRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IMRX
11/13/2026: IMRX (1-star) is currently NOT-A-BUY. Pass it for now.
Immuneering Corp is a clinical-stage biopharmaceutical stock focused on discovering and developing deep cyclic inhibitor medicines for advanced oncology indications. Its primary strengths lie in its proprietary discovery platform and advancing lead candidate atebimetinib into pivotal late-stage trials for pancreatic and lung cancers. The core investment opportunity rests on potential clinical breakthroughs and combination therapy synergies in high-unmet-need cancer markets. Key risks include an absence of product revenue, ongoing operating losses, and binary clinical trial outcomes. The stock suits risk-tolerant growth investors who should closely monitor upcoming clinical data readouts and regulatory updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Suits aggressive growth mandates seeking high-risk, high-reward clinical trial catalysts in oncology. |
| Momentum investor | Strong fit while signal remains positive | Treat Momentum fit as conditional on a positive Upturn signal and sharp clinical data-driven trading volume surges. |
| Value investor | Weak fit | Lacks traditional earnings, book value safety margins, or cash flows required for conventional value criteria. |
| Dividend investor | Weak fit | Does not pay dividends, rendering it completely unsuitable for income-focused strategies. |
| Low-risk investor | Weak fit | Exhibits high clinical binary risk and share price volatility characteristic of early-stage biotechs. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences sharp price swings reacting to clinical trial updates and biotech market sentiment. |
| Valuation risk | High | Valuation relies entirely on speculative future drug approvals rather than current fundamental earnings. |
| Competition risk (targeted oncology and MAPK pathway inhibition) | High | Numerous well-funded competitors are simultaneously developing alternative therapies for RAS/MAPK driven cancers. |
| Business quality | Medium | Features an innovative proprietary discovery platform, though offset by early-stage operational pre-revenue status. |
| Dividend income | Low / none | The company provides zero dividend yield. |
| Execution risk | High | Successful execution relies heavily on complex clinical trial outcomes and regulatory navigation. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 240.27M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 782.9K shares | Beta 0.46 | 52 Weeks Range 3.35 - 8.48 | Updated Date 11/15/2026 |
52 Weeks Range 3.35 - 8.48 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 44.06% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Research and Development | Future commercial sales or licensing milestones derived from oncology drug candidates such as atebimetinib and envometinib. | The company currently generates no product revenue and relies on external financing while advancing its drug pipeline. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 98.40M | Price to Sales(TTM) 563.62 |
Enterprise Value 98.40M | Price to Sales(TTM) 563.62 | ||
Enterprise Value to Revenue 191913.54 | Enterprise Value to EBITDA -1.53 | Shares Outstanding 64.76M | Shares Floating 49.28M |
Shares Outstanding 64.76M | Shares Floating 49.28M | ||
Percent Insiders 14.24 | Percent Institutions 58.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

